Positive associations have been found between rising obesity/body mass index (BMI) levels and Clostridium difficile infections (CDI) rates. Additionally, recent studies point to changes in the human microbiome as a potential mechanism for increased rates of CDI, along with the obvious increase in CDI prevalence associated with the use of proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD), a common occurrence in those with elevated BMI.
Metagenics Institute is a trusted, peer-to-peer, evidence-based educational resource for nutrition and personalized medicine.
At Metagenics Institute, we translate credible research with scientific integrity into innovative and actionable clinical
decision-making. Metagenics Institute supports a diverse practitioner base to optimize patient outcomes by shifting existing paradigms in healthcare. Our mission is to transform healthcare by inspiring and educating practitioners, and their patients, about personalized lifestyle medicine.
